Sato Shuntaro, Kawazoe Yurika, Murata Fumiko, Maeda Megumi, Fukuda Haruhisa
Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Ann Clin Epidemiol. 2025 Jan 24;7(2):50-60. doi: 10.37737/ace.25007. eCollection 2025 Apr 1.
The post-authorization safety study of a vaccine is an important public health task, and its results contribute to the decisions about whether to recommend a vaccination by estimating not only the risk ratio but also the risk difference. There are few reports of adjusted risk differences. We evaluated the statistical performance of the adjusted risk difference and its variance under a post-authorization safety study's settings (rare events, large sample, extreme exposure frequency).
Adjusted risk differences were estimated using ordinary least squares estimators in a linear regression model with a binary outcome, and their variances were estimated using the standard error from ordinary least squares and four types of robust variance. In a simulation, we evaluated the risk differences' performances using bias, coverage, and power and using data from the Vaccine Effectiveness, Networking, and Universal Safety study as an example of an actual post-authorization safety study.
The adjusted risk difference using ordinary least squares was not biased. Compared to the ordinary least squares' standard error, the robust variance achieved more appropriate coverage and higher power. With actual data, including 2 × 2 tables of exposure and outcome with zero, both the ordinary least squares and robust variance could be estimated.
In post-authorization safety study settings, the estimation of the risk difference using ordinary least squares and robust variance showed better performance than the typical ordinary least squares. These findings may prove beneficial for reporting risk difference in extreme settings such as post-authorization safety studies.
疫苗上市后安全性研究是一项重要的公共卫生任务,其结果不仅有助于通过估计风险比,还通过估计风险差值来做出是否推荐接种疫苗的决策。关于调整后风险差值的报告较少。我们评估了在疫苗上市后安全性研究的设定条件(罕见事件、大样本、极端暴露频率)下调整后风险差值及其方差的统计性能。
在具有二元结局的线性回归模型中,使用普通最小二乘估计量估计调整后的风险差值,并使用普通最小二乘的标准误和四种稳健方差估计其方差。在一项模拟中,我们以疫苗有效性、网络和通用安全性研究的数据作为实际疫苗上市后安全性研究的示例,通过偏差、覆盖率和检验效能评估风险差值的性能。
使用普通最小二乘法得到的调整后风险差值无偏差。与普通最小二乘的标准误相比,稳健方差实现了更合适的覆盖率和更高的检验效能。对于包含暴露与结局的2×2列联表中有零值的实际数据,普通最小二乘法和稳健方差均可进行估计。
在疫苗上市后安全性研究的设定条件下,使用普通最小二乘法和稳健方差估计风险差值的性能优于典型的普通最小二乘法。这些发现可能有助于在疫苗上市后安全性研究等极端情况下报告风险差值。